Figure 3.
Duration of treatment in phase IIa study of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine. PFS, progression‐free survival
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.